Abreva, an over-the-counter topical medication, contains the active ingredient docosanol 10%. Docosanol works by inhibiting the ability of the herpes simplex virus (HSV), which causes cold sores, to enter healthy cells [1]. This mechanism of action helps to prevent the further spread of the virus and can shorten the healing time of cold sores [1].
How quickly does Abreva start working?
Abreva is most effective when applied at the first sign of a cold sore, such as tingling, itching, or burning [2]. When used as directed, it can shorten healing time [1]. Clinical studies have shown that Abreva can shorten healing time by an average of one day compared to a placebo [3]. It should be applied five times a day for the recommended duration [2].
What are the side effects of using Abreva?
Common side effects associated with Abreva include headache, dizziness, nausea, and skin reactions like rash, itching, or redness at the application site [1]. While generally well-tolerated, individuals may experience mild irritation where the cream is applied [2].
Are there alternatives to Abreva for cold sore treatment?
Several other over-the-counter and prescription treatments are available for cold sores. These include other topical antiviral creams, oral antiviral medications (such as acyclovir, valacyclovir, and famciclovir), and pain relief creams or ointments [4]. Some people also use home remedies, although their efficacy is often not supported by clinical evidence [4].
How does Abreva compare to prescription cold sore medications?
Prescription oral antiviral medications are generally considered more potent and can be effective in treating widespread outbreaks or preventing recurrences, especially in individuals with frequent or severe cold sores [4]. Topical prescription antivirals may also offer faster or more comprehensive relief for some individuals [4]. Abreva, as an over-the-counter option, offers convenience and accessibility for managing cold sore symptoms and healing time [1].
When does Abreva's patent expire?
Information on the specific patent expiry for Abreva (docosanol 10% cream) is not readily available in the provided context. Drug patent information can be complex, with multiple patents often covering different aspects of a drug, including formulation, manufacturing, and method of use. For detailed patent expiry timelines, resources such as DrugPatentWatch.com can provide specific data [5].
Who manufactures Abreva?
Abreva is manufactured by GSK Consumer Healthcare [6].
Can Abreva prevent cold sores from coming back?
Abreva is designed to treat existing cold sores by preventing the virus from entering healthy cells and shortening the healing time [1]. It is not typically used as a preventative measure to stop cold sores from recurring [2]. However, by shortening the duration of an outbreak, it may reduce the frequency of viral shedding, potentially lessening the chances of transmission [1].
Sources:
[1] https://www.abreva.com/
[2] https://www.abreva.com/cold-sore-treatment/
[3] https://www.abreva.com/clinical-studies/
[4] https://www.healthline.com/health/cold-sore-treatment
[5] https://www.drugpatentwatch.com/
[6] https://www.gsk.com/